Ovarian low-grade serous carcinoma: a comprehensive update (Q38007297)

26 August 2017

title

Ovarian low-grade serous carcinoma: a comprehensive update (English)

1 reference

low-grade serous carcinoma

26 August 2017

1 reference

0 references

3

Lucas Minig

1 reference

26 August 2017

5

David M Gershenson

1 reference

26 August 2017

Ivan Diaz-Padilla

1

1 reference

26 August 2017

Anais L Malpica

series ordinal

2

1 reference

26 August 2017

Luis M Chiva

series ordinal

4

1 reference

26 August 2017

Antonio Gonzalez-Martin

series ordinal

6

1 reference

26 August 2017

language of work or name

English

0 references

publication date

30 April 2012

1 reference

26 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Gynecologic Oncology

1 reference

26 August 2017

volume

126

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

279-285

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Ovarian cancer is a heterogeneous disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Prognostic value of histologic grading of ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Grading ovarian serous carcinoma using a two-tier system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Low-grade serous ovarian cancer: a unique disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Epidemiology of low-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Etiologic heterogeneity for cervical carcinoma by histopathologic type, using comparative age-period-cohort models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Qualitative age interactions between low-grade and high-grade serous ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Mutations of the BRAF gene in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

BRAF Mutation in Papillary Thyroid Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

The Raf/MEK/ERK pathway: new concepts of activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

The MAP kinase pathway is required for entry into mitosis and cell survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Recurrent micropapillary serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Natural history and outcome of mucinous carcinoma of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.029

10.1016/J.YGYNO.2012.04.029

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference